Why DaVita, GoDaddy, and Applied Material Stocks are on Sale
Whenever Berkshire Hathaway’s (BRK-B) Warren Buffet sells a stock, look out below. The fund sold DaVita (DVA), causing shares to lose 11.09% last Friday.Berkshire sold $31.7 million worth of DVA stock, or a 1.0% stake. In addition, DaVita offered a weak outlook in its Q4/2024 report. For 2025, DaVita is forecasting operating income growth of 5.2%. This is a range of $2.01 - $2.16 billion. CFO Ackerman said that variable admissions, mortality, and mistreatment rates had an impact on its operating income range.GoDaddy (GDDY) lost 14.28% on Feb. 14, 2024, to close at $182.19. The firm, which handles dotcom registrations, posted revenue of $1.2 billion (+9.1% Y/Y). Average revenue per user could grow by 16% Y/Y. However, the revenue guidance range is conservative.Investors may consider Wix (WIX) instead since it offers better growth prospects.Applied Materials (AMAT) fell after posting Q1 results. Revenue grew by 6.9% Y/Y to $7.17 billion. However, total net revenue for Q2 is below consensus estimates. AMAT blamed China’s slow markets for the weak outlook. Still, the company enjoys strong margins on the Service side.In Q2, the firm expects strong growth from AI-related segments of the market. DRAM, Advanced Logic, and HBM are growth catalysts. However, NAND and DRAM growth will slow, partly a result of China’s slowdown continuing this year.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


